An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methylone, a synthetic cathinone sold as "bath salts"

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 45, Issue , 2013, Pages 64-72

  López Arnau, Raúl ^a   Martínez Clemente, José ^a   Carbó, Marcelli ^b,c   Pubill, David ^a   Escubedo, Elena ^a   Camarasa, Jorge ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c HOSPITAL DEL MAR   (Spain)

Author keywords

Locomotor activity; Methylone; Pharmacokinetics; PK PD modeling; Rat

Indexed keywords

DEMETHYLENATE; DRUG METABOLITE; METHYLONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; BRAIN LEVEL; CENTRAL NERVOUS SYSTEM; COMPARTMENT MODEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMETHYLATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; HYDROXYLATION; LIQUID CHROMATOGRAPHY; LOCOMOTION; MALE; MASS SPECTROMETRY; METHYLATION; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PROTEIN BINDING; RAT;

3'-HYDROXY-METHYLENEDIOXYMETHCATHINONE; 3'-OH-MDMC; 3,4-METHYLENEDIOXYCATHINONE; 3-HYDROXY-3-METHOXYMETHCATHINONE; 3-OH-4-MEO-MC; 4-HYDROXY-3-METHOXYMETHCATHINONE; 4-OH-3-MEO-MC; AIC; AKAIKE'S INFORMATION CRITERION; LC/MS; LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY; LOCOMOTOR ACTIVITY; MDC; MDMC; METHYLONE; METHYLONE (3,4-METHYLENEDIOXYMETHCATHINONE); PHARMACOKINETIC/PHARMACODYNAMICS ANALYSIS; PHARMACOKINETICS; PK/PD; PK/PD MODELING; RAT;

ALKALOIDS; ANIMALS; BIOLOGICAL AVAILABILITY; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; METHAMPHETAMINE; MOTOR ACTIVITY; PROTEIN BINDING; RATS;

EID: 84878374163     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.04.007     Document Type: Article

References (38)

1. Barrett P.H., Bell B.M., Cobelli C., Golde H., Schumitzky A., Vicini P., et al. SAAM II, simulation, analysis and modeling software for tracer and pharmacokinetics studies. Metabolism 1998, 47:484-492.
2. Baumann M.H., Ayestas M.A., Partilla J.S., Sink J.R., Shulgin A.T., Daley P.F., et al. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 2012, 37:1192-1203.
3. Birnie J.H., Grayson J. Observations on temperature distribution and liver blood flow in the rat. J Physiol 1952, 116:189-201.
4. Bossong M.G., Van Dijk J.P., Niesink R.J. Methylone and mCPP, two new drugs of abuse?. Addict Biol 2005, 10:321-332.
5. Boulanger-Gobeil C., St-Onge M., Laliberté M., Auger P.L.J. Seizures and hyponatremia related to ethcathinone and methylone poisoning. Med Toxicol 2012, 8:59-61.
6. Boyer E.W., Shannon M. The serotonin syndrome. N Engl J Med 2005, 352:1112-1120.
7. Brunt T.M., Poortman A., Niesink R.J., Van den Brink W. Instability of the ecstasy market and a new kid on the block, mephedrone. J Psychopharmacol 2010, 25:1543-1547.
8. Cawrse B.M., Levine B., Jufer R.A., Fowler D.R., Vorce S.P., Dickson A.J., et al. Distribution of methylone in four postmortem cases. J Anal Toxicol 2012, 36:434-439.
9. Cozzi N.V., Sievert M.K., Shulgin A.T., Jacobill P., Rhuolo A.E. Inhibition of plasma membrane monoamine transporters by betaketoamphetamines. Eur J Pharmacol 1999, 38:63-69.
10. Csajka C., Verotta D. Pharmacokinetic-pharmacodynamic modelling, history and perspectives. J Pharmacokinet Pharmacodyn 2006, 33:227-279.
11. Dayneka N.L., Garg V., Jusko W.J. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993, 21:457-478.
12. De la Torre R., Farré M. Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci 2004, 25:505-508.
13. Food, Drug Administration Center for Drug Evaluation, Research Guidance for Industry. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers (Available at), (Accessed 14 October 2012). http://http,//www.fda.gov/cder/guidance/index.htm.
14. Hadlock G.C., Webb K.M., McFadden L.M., Chu P.W., Ellis J.D., Allen S.C., et al. 4-Methylmethcathinone (mephedrone), neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 2011, 339:530-536.
15. Halifax D., Houston B.J. Evaluation of hepatic clearance prediction using in vitro data. Emphasis of fraction unbound in plasma and drug ionisation using a dataset of 107 drugs. J Pharm Sci 2012, 101:2645-2652.
16. Heller J., Hollyová J. Autoregulation of renal blood flow in the rat. Pflügers Arch Eur J Physiol 1977, 370:81-85.
17. Hitchcock S.A., Pennington L.D. Structure-brain exposure relationships. J Med Chem 2006, 49:7559-7583.
18. Kamata H.T., Shima N., Zaitsu K., Kamata A., Miki M., Nishikawa M., et al. Metabolism of the recently encountered designer drug, methylone, in humans and rats. Xenobiotica 2006, 36:709-723.
19. Kehr J., Ichinose F., Yoshitake S., Goiny M., Sievertsson T., Nyberg F., et al. Mephedrone, compared to MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and serotonin levels in nucleus accumbens of awake rats. Br J Pharmacol 2011, 64:1949-1958.
20. López-Arnau R., Martínez-Clemente J., Pubill D., Escubedo E., Camarasa J. Comparative neuropharmacology of three psychostimulant cathinone derivatives, butylone, mephedrone and methylone. Br J Pharmacol 2012, 167:407-420.
21. Mandema W., Tuk B., van Steveninck A.L., Breimer D.D., Cohen A.F., Danhof M. Pharmacokinetic-pharmacodynamic modelling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 1992, 51:715-728.
22. Martínez-Clemente J., Escubedo E., Pubill D., Camarasa J. Interaction of mephedrone with dopamine and serotonin targets in rats. Eur Neuropsychopharmacol 2012, 22:231-236.
23. Marusich J.A., Grant K.T., Blough B.E., Wiley J.L. Effects of synthetic cathinones contained in "bath salts" on motor behavior and a functional observational battery in mice. Br J Pharmacol 2012, 33:1305-1313.
24. Motbey C.P., Hunt G.E., Bowen M.T., Artiss S., McGregor I.S. Mephedrone (4-methylmethcathinone, 'meow'), acute behavioural effects and distribution of Fos expression in adolescent rats. Addict Biol 2011, 7:409-422.
25. Mueller D.M., Rentsch K.M. Generation of metabolites by an automated online metabolism method using human liver microsomes with subsequent identification by LC-MS(n), and metabolism of 11 cathinones. Anal Bioanal Chem 2012, 402:2141-2151.
26. Nagai F., Nonaka R., Satoh K., Kamimura S.H.K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 2007, 559:132-137.
27. Pearson J.M., Hargraves T.L., Hair L.S., Massucci C.J., Frazee C.C., Garg U., et al. Three fatal intoxications due to methylone. J Anal Toxicol 2012, 36:444-451.
28. Schoemaker R.C., van Gerven J.M., Cohen A.F. Estimating potency for the Emax model without attaining maximal effects. J Pharmacokinet Biopharm 1998, 26:581-593.
29. Sheiner L.B., Stanki D.R., Vozeh S., Miller R.D., Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics, application to d-tubocurarine. Clin Pharmacol Ther 1979, 25:358-371.
30. Shimizu E., Watanabe H., Kojima T., Hagiwara H., Fujisaki M., Miyatake R., et al. Combined intoxication with methylone and 5-MeO-MIPT. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:288-291.
31. Simmler L.D., Buser T.A., Donzelli M., Schramm Y., Dieu L.H., Huwyler J., et al. Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 2013, 168:458-470.
32. Sørensen L.K. Determination of cathinones and related ephedrines in forensic whole-blood samples by liquid-chromatography-electrospray tandem mass spectrometry. J Chromatogr B 2011, 879:727-736.
33. Spiller H.A., Ryan M.L., Weston R.G., Jansen J. Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clin Toxicol 2011, 49:499-505.
34. Vardakou I., Pistos C., Spiliopoulou C.H. Drugs for youth via Internet and the example of mephedrone. Toxicol Lett 2011, 201:191-195.
35. Warrick B.J., Wilson J., Hedge M., Freeman S., Leonard K., Aaron C. Lethal serotonin syndrome after methylone and butylone ingestion. J Med Toxicol 2012, 8:65-68.
36. Winstock A., Mitcheson L., Masden J. Mephedrone, still available and twice the price. Lancet 2010, 376:1537.
37. Yáñez J.A., Remsberg C.M., Sayre C.L., Forrest M.L., Davies N.M. Flip-flop pharmacokinetics-delivering a reversal of disposition, challenges and opportunities during drug development. Ther Deliv 2011, 2:643-672.
38. Zaitsu K., Katagi M., Kamata H.T., Kamata T., Shima N., Miki A., et al. Determination of the metabolites of the new designer drugs bk-MBDB and bk-MDEA in human urine. Forensic Sci Int 2009, 188:131-139.